Jaguar Health Explores Strategic Alternatives

MT Newswires Live06-22

Jaguar Health (JAGX) said Monday its board has started a process to explore strategic alternatives to maximize shareholder value.

The company said alternatives may include mergers, acquisitions, partnerships, joint ventures, licensing deals or other transactions.

The move is aligned with the expected completion of clinical work to support the filing of a new drug application for its crofelemer-based prescription drug candidate for rare intestinal failure diseases, Jaguar Health said.

Jaguar Health shares were down 1.3% in premarket activity Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment